ENDOLOGIX, INC. (NASDAQ:ELGX) Files An 8-K Submission of Matters to a Vote of Security Holders
Item 5.07Submission of Matters to a Vote of Security Holders.
Endologix, Inc. (the “Company”) held a Special Meeting of Stockholders (the “Special Meeting”) on Friday, February22, 2019 at 8:00 a.m., Pacific Time, at its corporate headquarters located at 2 Musick, Irvine, California 92618. As of January17, 2019, the record date for the Special Meeting, the Company had 103,453,661 shares of its common stock outstanding and entitled to vote, of which 78,775,196 shares of the Company’s common stock were present in person or represented by proxy and entitled to vote at the Special Meeting. The following is a brief description of the final voting results for the proposal submitted to a vote of the stockholders at the Special Meeting. This matter is described in more detail in the Company’s definitive proxy statement, which was filed with the Securities and Exchange Commission on January22, 2019.
Proposal No. 1: The Company’s stockholders approved an amendment to the Company’s Amended and Restated Certificate of Incorporation, as amended, to effect a reverse stock split of its issued and outstanding common stock at a ratio not less than1-for-5and not greater than1 for-10(inclusive), with the exact ratio to be set as a whole number within that range at the discretion of its board of directors before February22, 2020 without further approval or authorization of its stockholders. The Company’s board of directors may alternatively elect to abandon such proposed amendment and not effect the reverse stock split authorized by the Company’s stockholders, in its sole discretion.
|
Votes For |
Votes Against |
Votes Abstaining |
Broker Non-Votes |
|
74,003,939 |
4,740,198 |
31,059 |
About ENDOLOGIX, INC. (NASDAQ:ELGX)
Endologix, Inc. is engaged in developing, manufacturing, marketing and selling medical devices for the treatment of aortic disorders. The Company’s products are intended for the treatment of abdominal aortic aneurysms (AAA). The AAA products are built on one of two platforms, including traditional minimally invasive endovascular repair (EVAR) or endovascular sealing (EVAS), its solution for sealing the aneurysm sac while maintaining blood flow through two blood flow lumens. The EVAR products include the Endologix AFX Endovascular AAA System (AFX), the VELA Proximal Endograft (VELA) and the Endologix Powerlink with Intuitrak Delivery System (Intuitrak). The EVAS product is the Nellix EndoVascular Aneurysm Sealing System (Nellix EVAS System). Its EVAS product is the Nellix EndoVascular Aneurysm Sealing System (Nellix EVAS System). It offers accessories to facilitate the optimal delivery of its EVAR products, including compatible guidewires, snares, and catheter introducer sheaths.
